重组人血管内皮抑制素在晚期非小细胞肺癌化疗患者中的应用效果  

Application effect of recombinant human endostatin in patients with advanced non-small cell lung cancer undergoing chemotherapy

作　　者：马怡[1] 郑爽[1] 赫丽杰[1] MAYi;ZHENG Shuang;HAO Lijie(Department of Oncology,the People’s Hospital of Liaoning Province,Shenyang 110016,Liaoning,China)

机构地区：[1]辽宁省人民医院肿瘤科,沈阳1100160

出　　处：《癌症进展》2021年第6期603-606,637,共5页Oncology Progress

摘　　要：目的探讨重组人血管内皮抑制素在晚期非小细胞肺癌(NSCLC)化疗患者中的应用效果。方法依据随机数字表法将120例晚期NSCLC患者分为观察组和对照组,每组60例。对照组患者予以顺铂注射液治疗,观察组患者在对照组的基础上联合重组人血管内皮抑制素注射液治疗。比较治疗前后两组患者的肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原50(CA50)]水平、肺功能指标[用力肺活量占预计值百分比(FVC%)、第一秒用力呼气量(FEV1)以及最大通气量(MVV)]、外周血血管内皮生长因子(VEGF)和低氧诱导因子-1α(HIF-1α)水平、生活质量及免疫功能指标(CD3^(^(+))、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+))。结果治疗后,观察组患者的CYFRA21-1、CEA、CA50水平均低于对照组,FVC%、FEV1、MVV均高于对照组,外周血VEGF和HIF-1α水平均低于对照组,功能情况、情感情况、社会/家庭情况、生理状态评分均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为5.00%,低于对照组的16.67%,差异有统计学意义(P﹤0.05)。结论重组人血管内皮抑制素有利于降低晚期NSCLC化疗患者的肿瘤标志物及外周血VEGF和HIF-1α水平,改善肺功能,提高生活质量,增强免疫功能,降低不良反应发生率。Objective To investigate the application effect of recombinant human endostatin in patients with advanced non-small cell lung cancer(NSCLC)undergoing chemotherapy.Method 120 patients with advanced NSCLC were randomly divided into observation group and control group,with 60 cases in each group.Patients in the control group were treated with cisplatin injection,while patients in the observation group were treated with recombinant human endostatin injection on the basis of the control group.The levels of tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 50(CA50)],pulmonary function indicators[forced vital capacity as percentage of predicted value(FVC%),forced expiratory volume in first second(FEV1)and maximal voluntary ventilation(MVV)],peripheral blood vascular endothelial growth factor(VEGF)and hypoxia-inducible factor-1α(HIF-1α)levels,quality of life and immune function indicators(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))of two groups were compared before and after the treatment.Result After treatment,the levels of CYFRA21-1,CEA and CA50 in the observation group were lower than those in the control group,FVC%,FEV1 and MVV were higher than those in the control group,and the levels of VEGF and HIF-1αin peripheral blood were lower than those in the control group,the scores of functional status,emotional status,social/family status,and physiological status were all lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 5.00%,which was lower than that in the control group(16.67%),and the difference was statistically significant(P<0.05).Conclusion Recombinant human endostatin is beneficial to reduce tumor markers and peripheral blood VEGF and HIF-1αlevels in patients with advanced NSCLC undergoing chemotherapy,improve lung function and quality of life,enhance immune function,and reduce the incidence of adverse reactions.

关 键 词：重组人血管内皮抑制素 非小细胞肺癌 肿瘤标志物 血管内皮生长因子 低氧诱导因子-1Α 

分 类 号：R734.2[医药卫生—肿瘤]